Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio

Sponsor
University of Diyala
Study ID
NCT05822674
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
35 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

A blood glucose level of equal to or greater than 180 mg/dL that occurred during stress in a patient without diabetes mellitus (DM) is termed stress hyperglycemia (SH). The stress hyperglycemia ratio (SHR) is defined as the fasting blood glucose divided by the blood glucose level that is calculated from the glycosylated hemoglobin (HBA1c) value on admission. A significantly higher SHR is associated with worse prognostic biomarkers in diabetic patients with complications

Key Dates

Start date
Jan 1, 2022
Status verified
Apr 2023
Primary completion
Dec 31, 2022
Completion
Feb 1, 2023

Study Design

Enrollment
80 participants (actual)

Arms

  • Arm: Sitagliptin/metformin
    Patients with T2D treated with sitagliptin/metformin (50/500mg) once daily for 10 weeks
  • Arm: Empagliflozin/metformin
    Patients with T2D treated with empagliflozin/metformin (10/500mg) once daily for 10 weeks

Primary Outcome Measure

Stress hyperglycemia Ratio [ Time Frame: 10 week ]

Related Studies